This site is intended for healthcare professionals
News

Phase III PRO2TECT study of Vafseo meets primary endpoints in anemia due to chronic kidney disease.- Akebia Therapeutics

Read time: 1 mins
Last updated:26th Oct 2020
Published:25th Oct 2020
Condition: Anaemia and CKD
Type: drug
Register free for full access to medthority.com